Semaglutide and joint pain improvement — inflammatory marker correlation

PharmHunterJen said:

The dose-response is real but shallow at the top.

Saving this. It is the first explanation that did not require me to already understand it. Printing the relevant bit and taking it with me.

From the other side of the consultation, briefly.

Dr.RheumBOS said:

...but the FDA says semaglutide...

Interesting point. I want to add some regulatory nuance: the FDA labeling reflects the specific clinical trial data submitted for approval. Real-world clinical practice often extends beyond the FDA label based on emerging evidence and clinical judgment.

Example: semaglutide was first approved for diabetes (Ozempic), then obesity (Wegovy). The molecule didn't change — our understanding of its applications expanded. Similarly, semaglutide may evolve as more data accumulates.

TrialTracker_MD said:

Steady state is the thing most people miss.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

Correct me if the detail matters more than I have assumed.

One concrete data point for the thread. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.

Happy to go further on any of that.

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful.